Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits

Mark E. Potter, Edward E. Partridge, Hugh M. Shingleton, Seng Jaw Soong, Robert Y. Kim, Kenneth D. Hatch, J. Maxwell Austin

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors.

Original languageEnglish (US)
Pages (from-to)314-318
Number of pages5
JournalGynecologic oncology
Issue number3
StatePublished - Mar 1989

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits'. Together they form a unique fingerprint.

Cite this